Core Viewpoint - The company reported a loss for the fiscal year 2024 and will not distribute cash dividends, issue bonus shares, or increase capital from reserves [5]. Company Overview - The company has not changed its controlling shareholder or actual controller during the reporting period [5]. - The company has no preferred shareholders or related shareholding situations during the reporting period [5]. Financial Data and Indicators - The company plans to apply for a total credit limit of up to RMB 3.91 billion from various banks to meet operational and business development needs [6]. - The company will provide a joint liability guarantee of up to RMB 1 billion for its subsidiaries, while subsidiaries will provide a guarantee of up to RMB 2.5 billion for the company [6]. Important Matters - The company has fully provided for credit impairment losses on receivables from a subsidiary, Qingdao Huarun Pharmaceutical Co., Ltd., due to a debt resolution framework with Guoyao Medicinal Materials Co., Ltd. [7]. - The execution of the debt resolution framework remains uncertain, and the company is actively following up to maximize recovery of losses [7].
华仁药业股份有限公司